New adaptive method for phase I trials in oncology

Clinical Pharmacology and Therapeutics

Volumn 83, Issue 6, 2008, Pages 873-881

  Meille, C ^a   Gentet, J C ^a,b   Barbolosi, D ^a   Andre N ^b   Doz, F ^c   Iliadis, A ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

^b TIMONE HOSPITAL   (France)

^c INSTITUT CURIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL;

ADOLESCENT; ADULT; ARTICLE; CHILD; DATA ANALYSIS; DRUG TOLERABILITY; HUMAN; NEUROTOXICITY; NEUTROPENIA; ONCOLOGY; PATIENT SELECTION; PEDIATRICS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SIMULATION; TOXICITY;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I AS TOPIC; HUMANS; MAXIMUM TOLERATED DOSE; MEDICAL ONCOLOGY; MODELS, BIOLOGICAL; RETROSPECTIVE STUDIES;

EID: 43949096591     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100383     Document Type: Article

References (27)

1. NCI-CTC. National Cancer Institute - Common Toxicity Criteria Version 2.0. 〈http://ctep.cancer.gov/forms/CTCv20_4-30-992.pdf〉 (1999).
2. Edler, L. Overview of phase I trials. In Handbook of Statistics in Clinical Oncology (ed. Crowley J.) 1-34 (Marcel Dekker, New York, 2001).
3. Storer, B.E. Design and Analysis of Phase I Clinical Trials (Wiley, New York, 1998).
4. Lin, Y. & Shih, W.J. Statistical properties of the traditional algorithm-based designs for phase I cancer clinical trials. Biostatistics 2, 203-215 (2001).
5. Mick, R. & Ratain, M.J. Model-guided determination of maximum tolerated dose in phase I clinical trials: evidence for increased precision. J. Natl. Cancer Inst. 85, 217-223 (1993).
6. O'Quigley, J., Pepe, M. & Fisher, L. Continual reassessment method: a practical design for phase I clinical trials in cancer. Biometrics 46, 33-48 (1990).
7. O'Quigley, J. & Shen, L.Z. Continual reassessment method: a likelihood approach. Biometrics 52, 673-684 (1996).
8. Piantadosi, S., Fisher, J.D. & Grossman, S. Practical implementation of a modified continual reassessment method for dose-finding trials. Cancer Chemother. Pharmacol. 41, 429-436 (1998).
9. O'Quigley, J. Curve-free and model-based continual reassessment method designs. Biometrics 58, 245-249 (2002).
10. Thall, P.F., Lee, J.J., Tseng, C.H. & Estey, E.H. Accrual strategies for phase I trials with delayed patient outcome. Stat. Med. 18, 1155-1169 (1999).
11. Doz, F. et al. Phase I trial and pharmacological study of a 3-hour paclitaxel infusion in children with refractory solid tumours: a SFOP study. Br. J. Cancer 84, 604-610 (2001).
12. Marsoni, S., Ungerleider, R.S., Hurson, S.B., Simon, R.M. & Hammershaimb, L.D. Tolerance to antineoplastic agents in children and adults. Cancer Treat. Rep. 69, 1263-1269 (1985).
13. Grossman, S.A. et al. Increased 9-aminocamptothecin dose requirements in patients on anticonvulsants. Cancer Chemother. Pharmacol. 42, 118-126 (1998).
14. Tranchand, B. et al. Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors. Cancer Chemother. Pharmacol. 41, 281-291 (1998).
15. Meille, C. et al. Retrospective analysis of data from a phase I trial with a new adaptive method. In American Society of Clinical Oncology Annual Meeting Proceedings. Part I, Vol. 25, No. 18S, p 1067 (Journal of Clinical Oncology, Chicago, 2007).
16. Johnson, N., Kotz, S. & Balakrishnan, N. Discrete Multivariate Distributions (Wiley, New York, 1997).
17. Abramowitz, M. & Stegun, I.A. Handbook of Mathematical Functions (Government Printing Office, Washington DC, 1964).
18. Rogatko, A., Babb, J.S., Wang, H., Slifker, M.J. & Hudes, G.R. Patient characteristics compete with dose as predictors of acute treatment toxicity in early phase clinical trials. Clin. Cancer Res. 10, 4645-4651 (2004).
19. Bekele, B.N. & Thall, P.F. Dose-finding based on multiple toxicities in a soft tissue sarcoma trial. J. Am. Stat. Assoc. 99, 26-35 (2004).
20. Cheung, Y.K. & Chappell, R. Sequential designs for phase I clinical trials with late-onset toxicities. Biometrics 56, 1177-1182 (2000).
21. Storer, B.E. Design and analysis of phase I clinical trials. Biometrics 45, 925-937 (1989).
22. Kalbfleisch, J.D. & Prentice, R.L. The Statistical Analysis of Failure Time Data 2nd edn. (Wiley, Hoboken, NJ, 2002).
23. MATLAB. High-performance Numeric Computation and Visualization Software (The Math Work, Natick, MA, 2004).
24. Kocherlakota, S. & Kocherlakota, K. Bivariate Discrete Distributions (Marcel Dekker, New York, 1992).
25. Cheng, J.D. et al. Individualized patient dosing in phase I clinical trials: the role of escalation with overdose control in PNU-214936. J. Clin. Oncol. 22, 602-609 (2004).
26. Piantadosi, S. & Liu, G. Improved designs for dose escalation studies using pharmacokinetic measurements. Stat. Med. 15, 1605-1618 (1996).
27. Seber, G.A.F. & Wild, C.J. Nonlinear Regression Analysis (Wiley, New York, 1989).